News

New Clinical Data Demonstrates Three Years of Continuous Treatment with Dual-Acting LEQEMBI® (lecanemab-irmb) Continues to Significantly Benefit Early Alzheimer’s Disease Patients Presented at The Alzheimer’s Association International Conference (AAIC) 2024

Biogen, Beckman Coulter and Fujirebio to Collaborate on Blood-Based Biomarkers and Test for Tau Pathology in Alzheimer’s Disease

Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union

Sage Therapeutics and Biogen Announce Topline Results from Phase 2 KINETIC 2 Study of SAGE-324 (BIIB124) for the Treatment of Essential Tremor

“LEQEMBI®” (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in Israel

“LEQEMBI®” (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in Hong Kong

Biogen Completes Acquisition of Human Immunology Biosciences

“LEQEMBI®” (Lecanemab) for the Treatment of Alzheimer’s Disease Launched in China

Biogen to Report Second Quarter 2024 Financial Results August 1, 2024

TOFIDENCE™ (tocilizumab), a Biosimilar Referencing ROACTEMRA®, Approved in the European Union